Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment.
Chagas disease
chagas cardiomyopathy
electrocardiogram
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
11
09
2018
accepted:
14
01
2019
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
23
2
2019
Statut:
epublish
Résumé
The objective of the study was to better understand the impact of antitrypanosomal treatment on the evolution of Chagas-related, prognostically important electrocardiogram (ECG) abnormalities. Initial and posttreatment ECGs were obtained in a prospective cohort of Chagas patients treated with nifurtimox or benznidazole and compared to an untreated cohort. Electrocardiogram disease progression was compared in those with and without baseline abnormalities pre- and posttherapy. Fifty-nine patients were recruited in the treatment arm and followed for an average of 3.9 years. There were no differences between ECG groups with regards to follow-up, age, baseline ejection fraction, or therapy. In the treated cohort, 0 of 30 patients with normal ECGs developed an abnormal ECG compared with 7 of 29 patients with baseline ECG abnormalities who developed new ECG abnormalities ( Over an average follow-up of 3.9 years, treated patients with normal baseline ECGs did not have significant changes during a course of treatment; however, those with baseline abnormal ECGs had significant progression of their conduction system disease despite treatment, and those without treatment also experienced a progression of ECG disease. These preliminary results suggest that Chagas patients with normal ejection fraction and normal ECG may benefit the most from antitrypanosomal treatment.
Sections du résumé
BACKGROUND
BACKGROUND
The objective of the study was to better understand the impact of antitrypanosomal treatment on the evolution of Chagas-related, prognostically important electrocardiogram (ECG) abnormalities.
METHODS
METHODS
Initial and posttreatment ECGs were obtained in a prospective cohort of Chagas patients treated with nifurtimox or benznidazole and compared to an untreated cohort. Electrocardiogram disease progression was compared in those with and without baseline abnormalities pre- and posttherapy.
RESULTS
RESULTS
Fifty-nine patients were recruited in the treatment arm and followed for an average of 3.9 years. There were no differences between ECG groups with regards to follow-up, age, baseline ejection fraction, or therapy. In the treated cohort, 0 of 30 patients with normal ECGs developed an abnormal ECG compared with 7 of 29 patients with baseline ECG abnormalities who developed new ECG abnormalities (
CONCLUSIONS
CONCLUSIONS
Over an average follow-up of 3.9 years, treated patients with normal baseline ECGs did not have significant changes during a course of treatment; however, those with baseline abnormal ECGs had significant progression of their conduction system disease despite treatment, and those without treatment also experienced a progression of ECG disease. These preliminary results suggest that Chagas patients with normal ejection fraction and normal ECG may benefit the most from antitrypanosomal treatment.
Identifiants
pubmed: 30793005
doi: 10.1093/ofid/ofz012
pii: ofz012
pmc: PMC6377566
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz012Références
Clin Microbiol Rev. 1999 Apr;12(2):210-23
pubmed: 10194457
Heart. 2002 Dec;88(6):559-60
pubmed: 12433875
Rev Esp Cardiol. 2005 Sep;58(9):1037-44
pubmed: 16185616
Ann Intern Med. 2006 May 16;144(10):724-34
pubmed: 16702588
Rev Soc Bras Med Trop. 2007 Jan-Feb;40(1):1-10
pubmed: 17486245
Mem Inst Oswaldo Cruz. 1991 Apr-Jun;86(2):187-200
pubmed: 1842413
Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:167-80
pubmed: 19753472
Lancet. 2010 Apr 17;375(9723):1388-402
pubmed: 20399979
J Electrocardiol. 2012 Jan-Feb;45(1):43-8
pubmed: 21704321
N Engl J Med. 2011 Jun 30;364(26):2527-34
pubmed: 21714649
PLoS Negl Trop Dis. 2013;7(2):e2078
pubmed: 23469305
J Antimicrob Chemother. 2013 Sep;68(9):2164-9
pubmed: 23645584
Am J Trop Med Hyg. 2015 Jan;92(1):39-44
pubmed: 25385865
Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43
pubmed: 25671846
Am J Pathol. 2015 Jun;185(6):1537-47
pubmed: 25857229
Cardiovasc Pathol. 1993 Apr-Jun;2(2):101-6
pubmed: 25990604
N Engl J Med. 2015 Oct;373(14):1295-306
pubmed: 26323937
J Cardiovasc Electrophysiol. 2016 Feb;27(2):161-9
pubmed: 26412204
PLoS Negl Trop Dis. 2016 Mar 14;10(3):e0004508
pubmed: 26974551
PLoS Negl Trop Dis. 2016 May 09;10(5):e0004651
pubmed: 27158908
PLoS One. 2016 Jun 16;11(6):e0157597
pubmed: 27308824
PLoS Negl Trop Dis. 2016 Nov 7;10(11):e0005033
pubmed: 27820837
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005244
pubmed: 28056014
PLoS Negl Trop Dis. 2018 Jun 13;12(6):e0006567
pubmed: 29897909
Rev Soc Bras Med Trop. 2018 Sep-Oct;51(5):570-577
pubmed: 30304260
Circulation. 2018 Sep 18;138(12):e169-e209
pubmed: 30354432
PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006814
pubmed: 30383777
J Electrocardiol. 2018 Nov - Dec;51(6):1039-1043
pubmed: 30497727
Arq Bras Cardiol. 1985 Oct;45(4):249-56
pubmed: 3835868
Am Heart J. 1994 Jan;127(1):151-62
pubmed: 8273735
Am Heart J. 1996 Feb;131(2):301-7
pubmed: 8579025